

GC-TOF/MS-Based Metabolomics Analysis to Investigate the Antimicrobial Activity of N-Acetylcysteine in the Plant-Pathogen *Xanthomonas Citri* Subsp. *Citri*

Simone Cristina Picchi

Instituto Agronomico de Campinas - SP

Mariana Souza e Silva

Instituto Agronomico de Campinas - SP

Luiz Leonardo Saldanha

Sao Paulo State University

Henrique Ferreira

Sao Paulo State University

Marco Aurélio Takita

Instituto Agronomico de Campinas - SP

Camila Caldana

Laboratório Nacional de Ciência e Tecnologia do Bioetanol

Alessandra Alves Souza (✉ desouza@ccsm.br)

Instituto Agronomico de Campinas - SP

Research Article

Keywords: NAC, Metabolomics, *Xanthomonas*

Posted Date: February 24th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-228895/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on July 30th, 2021. See the published version at <https://doi.org/10.1038/s41598-021-95113-4>.

1 **GC-TOF/MS-based metabolomics analysis to investigate the antimicrobial activity of**
2 **N-Acetylcysteine in the plant-pathogen *Xanthomonas citri* subsp. *citri***

3

4 Simone Cristina Picchi¹, Mariana de Souza e Silva¹, Luiz Leonardo Saldanha², Henrique
5 Ferreira², Marco Aurélio Takita¹, Camila Caldana^{3*} and Alessandra Alves de Souza^{1**}.

6

7 ¹Centro de Citricultura “Sylvio Moreira” – Instituto Agronômico de Campinas,
8 Cordeirópolis, São Paulo, 13490-970, Brazil.

9 ²Departamento de Bioquímica e Microbiologia, Instituto de Biociências, Universidade
10 Estadual Paulista, Rio Claro, São Paulo, 13506-900, Brazil.

11 ³Centro Nacional de Pesquisa em Energia e Materiais (CNPEM), Campinas, São Paulo,
12 13083-100 Brazil.

13 *Present address: Max-Planck-Institut für Molekulare Pflanzenphysiologie,
14 Wissenschaftspark Golm, Am Mühlenberg 1, 14476 Potsdam, Germany.

15 **corresponding autor: *desouza@ccsm.br*

16

17

18 N-Acetylcysteine (NAC) is an antioxidant, anti-adhesive, and antimicrobial compound. Even
19 though there is much information regarding the role of NAC as an antioxidant and anti-
20 adhesive agent, little is known about its antimicrobial activity. In order to assess its mode of
21 action in bacterial cells, we investigated the metabolic responses triggered by NAC at neutral
22 pH. As a model organism, we chose the Gram-negative plant pathogen *Xanthomonas citri*
23 subsp. *citri* (*X. citri*), the causal agent of citrus canker disease, due to the potential use of
24 NAC as a sustainable molecule against phytopathogens dissemination in citrus cultivated
25 areas. In presence of NAC, cell proliferation was affected after 4 hours, but damages to the
26 cell membrane were observed only after 24 hours. Targeted metabolite profiling analysis
27 using GC-MS/TOF unravelled that NAC seems to be metabolized by the cells affecting
28 cysteine metabolism. Intriguingly, glutamine, a marker for nitrogen status, was not detected
29 among the cells treated with NAC. The absence of glutamine was followed by a decrease in
30 the levels of the majority of the proteinogenic amino acids, suggesting that the reduced
31 availability of amino acids affect protein synthesis and consequently cell proliferation.

32

33 **Introduction**

34 Bacterial biofilms are responsible for many diseases in plants, animals and humans in
35 which biofilm formation is an essential step for host colonization and disease development ¹⁻
36 ⁴. The difficulty for biofilm eradication in clinical and environmental settings resides in their
37 multiple resistance mechanisms such as poor antimicrobial penetration, slow growth,
38 adaptive stress responses and formation of persister cells ⁵⁻⁹.

39 The bacterium *Xanthomonas citri* subsp. *citri*, the causing agent of citrus canker
40 disease, is one of the most destructive phytopathogen in the citrus agribusiness¹⁰. Among its
41 virulence factors, biofilm formation plays an essential role at early stages of infection by
42 enhancing bacterial epiphytic survival ¹¹⁻¹⁴. Importantly, multiple mutants of *X. citri* impaired
43 in biofilm formation consistently exhibit a decrease in bacterial growth *in planta* and have
44 reduced ability to elicit canker symptoms in susceptible host ¹⁵. This led us to hypothesize
45 that compounds inhibiting biofilm formation may reduce its infection and enhance the control
46 of citrus canker disease. Indeed, it was previously verified that N-Acetylcysteine (NAC), a
47 cysteine analogue known to disrupt disulfide bonds in bacterial biofilm ¹⁶, was able to disrupt
48 biofilm formation in *X. citri* as well as kill bacterial cells leading to a decrease in plant
49 disease¹⁷.

50 NAC is largely used in humans to decrease biofilm-based infections due to its
51 properties as a mucolytic agent that breaks biofilms and also improves body healthy as an
52 antioxidant molecule ^{16, 19-20}. Furthermore, NAC has antimicrobial effect inhibiting growth
53 of many different Gram-negative and Gram-positive bacteria ^{8, 20, 21-24}. Therefore, NAC is
54 emerging as an interesting potential therapeutics molecule since it does not induce genetic
55 resistance and is beneficial to human health ^{9, 16}.

56 Despite the well-established role of NAC as a mucolytic agent and an antioxidant
57 molecule, the mode of action of this compound in triggering death of prokaryotic cells is still
58 unknown. It has been shown that due to the acid trait of NAC ($\text{pH} < \text{pKa}$) it can penetrate
59 the biofilm matrix and eventually kill 100% of the bacteria embedded in the biofilm ⁹,
60 however many authors have shown the antimicrobial effect of NAC even at neutral pH ^{8, 17,}
61 ^{20, 25, 26}. These results indicate that other factors might be also involved with the NAC
62 antimicrobial property.

63 In this study we used the Gram-negative plant-pathogen *X. citri* as model to investigate
64 the impact of NAC treatment in the primary metabolism of prokaryotic cells. By performing
65 a time course analysis, we found out that growth started to be impaired after 4h of NAC
66 treatment, matching the metabolic alterations in most of the proteogenic amino acids. Our
67 findings indicated that NAC interferes with nitrogen metabolism, reducing the availability of
68 amino acids for protein synthesis, which might contribute to reduction in cell proliferation
69 and activation of cell death. A molecular network was created, and compounds annotation
70 was made on the basis of comparison with spectral database. When the metabolomics MVDA
71 results were integrated in a multi-informational MN²⁷, this approach highlighted metabolites
72 that differed significantly with NAC treatment.

73

74 **Results**

75 **Effect of NAC on bacterial cell growth.** In previous experiments, we verified that 8 mg/mL
76 of NAC was able to kill *X. citri* cells after 24 hours of growth in a population starting from
77 10⁴ CFU/mL at the beginning of the treatment¹⁷. In this study, we analyzed the *X. citri* growth
78 curve in the presence of 8 mg/mL of NAC for 24 hours to understand the primary metabolic
79 changes that affect cell growth. In order to assess the metabolic changes, we used an initial
80 population of 10⁶ CFU/mL instead of 10⁴ CFU/mL used by Picchi et al¹⁷, to be able to impair
81 their growth upon NAC treatment without killing the cells (Supplementary Fig. S1).

82 Exponential growth was observed 4 hours after *X. citri* inoculation, while the presence
83 of NAC causes a significant reduction at this time point (Fig. 1). The cells concentration
84 increased from 10⁶ to 10¹⁰, but it was observed a significant reduction in cell growth in
85 presence of NAC, increasing only one log, from 10⁶ to 10⁷, i.e., three logs difference in
86 relation to the control. Aiming to analyze whether NAC was disrupting the cell membrane,
87 we used SYTO9 and propidium iodide (PI) methodology to assess cell viability. SYTO9
88 penetrates both live and dead cells, whereas PI stains only cells with corrupted cell membrane
89 and intercalates with the nucleic acids. Despite the significant lower number of cells 4h after
90 NAC treatment, the percentage of dead cells did not show a significant difference with the
91 untreated control until 12 hours (Fig. 2a and Fig. 2b). However, after 24 hours a significant
92 higher number of cells stained with IP (here represented in red) was observed following
93 treatment with NAC, when approximately 20% of cells had their membrane permeabilized.

94 These results demonstrated that the mechanism by which NAC acts as an antimicrobial
95 molecule precedes disruption of the cell membrane.

96

97 **Metabolic changes in *X. citri* subsp. *citri* cells exposed to NAC.** To investigate changes on
98 primary metabolism of the bacteria incubated with NAC, we performed a well-established
99 gas chromatography-mass spectrometry (GC-MS) method ²⁸. Since NAC was not included
100 in the compound reference library ²⁹, we first analyzed NAC standard in GC-MS. We were
101 able to annotate two peaks at RI of 554630 and 622850 and the selective masses of 218, 260,
102 100, 115, 364, 173 and 184, 156, 114, 232, 274, 100, respectively. These features were
103 included in the reference library and used for the annotation of the metabolites. For NAC
104 quantification, we always considered the peak with the highest intensity.

105 As bacterial growth was already reduced after 4h of NAC treatment, we carried out a
106 time series experiment in which samples were harvested during the lag phase (i.e., 0, 2, 4
107 hours) and exponential phase (6, 12 and 24h) to better assess the influence of NAC in
108 bacterial growth. A total of 55 metabolites with known chemical structures were identified
109 by a targeted analysis ³⁰, except for glutamine all metabolites were detected in both
110 treatments. These metabolites covered primary metabolism pathways which includes amino
111 acid metabolism, glycolysis, and the tricarboxylic acid (TCA) cycle (Supplementary Table
112 S1). Hierarchical clusters analyses (HCA) clearly split the samples into two main branches:
113 one corresponding to NAC treatment and control samples (Fig. 3a). While samples treated
114 with NAC did not show a define separation along the time points, the control samples could
115 be further grouped into early phase (1-6h) and late exponential (12-24h) growth. In order to
116 get a better overview of the metabolites leading these cluster patterns, we performed principal
117 component analysis (Fig. 3b). Similarly, to the HCA results, PC1 separates the sample
118 according to the treatment, explaining 46% of the variation. Not surprisingly, inspection of
119 the loadings responsible for the PC1 separation shows NAC and cysteine largely contributed
120 to the discrimination of the treatments followed by few amino acids and sugars
121 (Supplementary Table S2). The dynamic of the cell proliferation was captured by PC2, which
122 explains 26% of the variation in this dataset. This dynamic is, however, much more clearly
123 in the control samples than in the NAC-treated samples. Such trend was mainly related to the

124 differences in amino acids, glycerol, adenine, and trehalose. These results suggest that NAC
125 treatment leads to metabolic rewiring which might affect cell proliferation.

126

127 **Determinants of cell growth-related metabolic changes.** Metabolism directly participates
128 in cell division and proliferation. As NAC application seems to interfere in cell proliferation,
129 we first focused on the metabolic changes along the *X. citri* growth in the control condition.
130 We selected only the metabolites, in which at least one time-point was significantly different
131 with respect to the time point 0 in the control samples, resulting in 32 compounds
132 (Supplementary Table S3). In order to facilitate the comparison among the metabolites, we
133 normalized the value of each metabolite in reference to their levels at time-point 0. We next
134 carried out to k-means clustering analysis for the identification of metabolic modules whose
135 patterns change along the growth curve (Fig. 4). The analysis allowed the discrimination of
136 4 clusters. Early changes in growth were mainly captured by the clusters 2, 3 and 4. Despite
137 the slightly different dynamic in the response, clusters 3 and 4 includes metabolites whose
138 levels follow a rapid lowered of their levels along the growth curve. Cluster 2 captured the
139 metabolites that have their levels increased within the first hours of the growth curve and
140 progressively decrease when growth enters the exponential phase. Most of the metabolites
141 present in these three clusters seems to be important for the synthesis of the building blocks
142 of the cells, as it is the case for adenine (nucleic acids); glucose, talose, mannose and trehalose
143 (carbohydrates); succinate and hydroxypyruvate, which are precursors of TCA to generate
144 energy and provides C skeleton for anabolic processes. Furthermore, two important nitrogen
145 sources, asparagine and glutamine, as well as other proteogenic amino acids, such as alanine,
146 isoleucine, proline, phenyalanine and serine were also part of these clusters. Metabolic
147 changes related to the late stages of the growth curve were only identified in the cluster 1,
148 including some amino acids valine, glycine, threonine, and tyrosine and other non-
149 proteogenic amino acids like GABA, 5-oxoproline, whose levels positively correlates with
150 the progression of the growth curve.

151

152

153

154 **NAC affects aminoacid metabolism in bacterial cells.** To dissect the possible impact of
155 NAC on metabolism, we next compared the dynamics of the metabolites along the growth
156 curve when cells were treated or not with this compound using a heatmap analysis (Fig. 5).
157 As already highlighted by the PCA, NAC and cysteine levels dramatically increased over
158 time. These changes were followed by slight increases in the levels of serine and
159 hydroxypyruvate that are precursors on the cysteine pathway. Interestingly, glutamine was
160 completely absent in the samples treated with NAC regardless of the time point. Glutamine
161 is an important source of nitrogen in bacteria as it is required for the synthesis of a range of
162 nitrogen-containing compounds, including amino acids ³¹.

163 Intriguingly, many amino acid levels (e.g., branched- and aromatic- amino acids,
164 proline, methionine) were decreased over time in the NAC treated samples, including that
165 NAC might interfere with nitrogen metabolism. Furthermore, cells treated with NAC seems
166 to display a depletion in the C source in the late time points (fructose, glucose, trehalose etc.).
167 Overall, the results suggest that the bacteria cells must metabolizing a lot of cysteine that
168 ends up failing to eliminate so much toxicity and this affects the absorption of nutrients and
169 the cell redox.

170

171 **Untargeted identification of biomarkers of NAC treatment.** In order to discover
172 biomarkers using both supervised model (OPLS) and untargeted data analysis in an
173 integrated manner, a statistically informed molecular network approach was carried ²⁷. The
174 MN allows not only to organize and classify a high number of mass spectra by similarity
175 accelerating their annotation by comparison with spectral databases from different platforms
176 but also allows to enrich the MN with metadata ³².

177 For this, the GC-TOF/MS data processing following the workflow described in Elie,
178 Santerre and Touboul ³³, allowed the detection of 1,082 MS spectra. These were submitted
179 to the Global Natural Products Social Network platform (GNPS) to generate a unique MN
180 following the GC-MS workflow ³⁴. The spectrum of each node was searched against the
181 spectral database available at the GNPS and allowing the annotation of 269 (25%)
182 metabolites with cosine (similarity) score ranging from 0.98 to 0.50. Metabolites presenting
183 cosine score > 0.75 were selected and annotated in the MN as presented below.

184 Subsequently, to identify untargeted markers in the MN, we integrated the statistical
185 results from the metabolomics MVDA in the MN, when 15 features with a VIP value > 1.0
186 from the OPLS analysis (Supplementary Fig. S2) were integrated as a metadata in the MN.
187 This metadata can be visualized through the size of the node in the MN. Such features were
188 highlighted in the MN using larger nodes. Nodes with VIP values below 1 were kept in lower
189 node size. In addition, the relative mass signal intensity of metabolites for NAC treatment
190 and the untreated control samples can be visualized through the node colours. Furthermore,
191 the relative MS signal intensity of metabolites at 0, 1, 2, 4, 6, 12 and 24 hours following the
192 NAC treatment is displayed in the bar plot next to the node. The full statistically informed
193 MN is provided in the Supporting information (Supplementary Fig. S3).

194 Using this method, it was possible to identify clusters with compounds that exhibit VIP
195 values representing variance between NAC and control groups and their dynamics over time.

196 After analysis of the statistically informed MN, clusters were selected based on their
197 node size. Using this criteria, 10 clusters were selected, herein named MN₁-MN₁₀. A total of
198 21 compounds were evidenced in the selected clusters and assigned biomarker potential. Fig.
199 6 shows the selected clusters and annotated compounds in detail.

200 As demonstrated in the selected clusters, particularly to cells incubated with NAC,
201 amino acids such as L-proline, L-leucine, L-valine, L-lysine, lyxosylamine and tyrosine were
202 present in lower levels when compared with control. Carbohydrates as D-xylose, D-glucose,
203 mannitol, D-tagatose, and D-ribose were present in lower levels as well and decreased over
204 time as expected. On the other hand, metabolites such as glutamate, asparagine, methyl-3-
205 methoxy-2-naphthoate, 5-methylcytosine and nitrotyrosine were found in high levels and to
206 increase over time when compared to control.

207 These results are in agreement and complement the target approach evidencing clusters
208 with amino acids and carbohydrates as markers for NAC treatment.

209 In order to map these compounds on to bacterial metabolic pathways, a list with the
210 identified compounds in the depicted clusters from the MN was submitted to pathway impact
211 analysis.

212

213 **Pathway impact analysis.** In an attempt to identify deregulated pathways in which these
214 metabolites are related, the target and untarget identified metabolites which differed

215 significantly were mapped on to bacterial metabolic pathways. For this, a targeted analysis
216 integrating enrichment and topology analyses was performed using the Pathway Analysis
217 workflow available on the MetaboAnalyst online platform. The pathways impact analysis
218 shows all matched pathways according to the p values from the pathway enrichment analysis
219 and pathway impact values from the pathway topology analysis for up- and down-regulated
220 metabolites separately. The identified pathways with high impact values are represented (Fig.
221 7). The detailed results of pathway analysis with significance levels and impact are presented
222 in Supplementary Table S4.

223 This analysis showed that several pathways of amino acids, nitrogen and carbohydrate
224 metabolism were significantly disturbed. Twelve pathways with P value < 0.05 were
225 considered to be significantly affected after treatment with NAC. The down-regulated
226 metabolites were located into amino sugar and nucleotide sugar metabolism and
227 dicarboxylate metabolism, valine, leucine and isoleucine biosynthesis as well as degradation
228 and novobiocin biosynthesis. The up-regulated metabolites were found in alanine, aspartate
229 and glutamate metabolism, carbapenem biosynthesis, nitrogen metabolism, D-glutamine and
230 D-glutamate metabolism, cyanoamino acid metabolism, and taurine and hypotaurine
231 metabolism. Some of the selected metabolites which were both up- and down-regulated
232 shared the aminoacyl-tRNA biosynthesis.

233

234 **Discussion**

235 NAC is a cysteine analogue which has a mucolytic action due to the ability to break
236 disulphide bridges of extracellular proteins and consequently disrupts bacterial biofilm. In
237 addition, NAC is a well-described antioxidant and safety molecule used in medicine¹⁶. The
238 molecular mechanisms underlying these two beneficial effects are well known, however, the
239 mechanism by which NAC acts as antimicrobial is still poorly investigated. Recently it was
240 shown that the acid pH of NAC is the key factor that facilitated the drug in entering the
241 *Pseudomonas aeruginosa* biofilm matrix and killing the bacteria by diffusing through the
242 cell wall. As the pH inside the bacteria is high (around 7.6), NAC dissociates and acidifies
243 the cytoplasm, hence denaturing proteins and causing DNA damage leading to the cell death⁹.
244 On the other hand, the authors found that there was swelling of the bacterial colonies only in
245 the presence of NAC which confirmed that the killing of bacteria at pH 3.4 was due to the

246 action of NAC and not merely a pH effect. Thus, to avoid the interference of acid pH, in this
247 study we adjusted the NAC solution to pH 6.8 aiming to investigate only the antimicrobial
248 effect of NAC in bacterial cells. The neutral pH used in our experiments could explain why
249 it was necessary more time to kill *X. citri* (8mg/mL of NAC for 24 hours and Supplementary
250 Fig. S1)¹⁷ compared with *P. aeruginosa* (10mg/mL of NAC for 15 min)⁹ using a diluted
251 culture to start cell growth. Likewise, no difference in the staining with SYTO9 and PI were
252 observed in our experiments using NAC until 12 hours of incubation. Thus, as PI penetrates
253 in the disrupted cell membrane, we can conclude that the antimicrobial effect of NAC
254 precedes cell membrane damage, since a significant percentage of cells with permeabilized
255 membranes in presence of NAC was observed only after 24 hours of incubation (Fig. 2), but
256 the impairment in cell growth occurred just after 4 hours (Fig. 1). Therefore, NAC increased
257 the doubling time of the bacterial population, affecting the growth curve. Since there is no
258 significative difference in the balance of potentially live and dead cells until 24 h of NAC
259 incubation, this could result from two situations, just a small fraction of the population is
260 actively dividing or the metabolism of the whole population of living cells is low, increasing
261 the doubling time. In addition, our results demonstrated that NAC even at neutral pH is
262 penetrating the bacterial cells causing alteration and decreasing cell growth (Fig. 1).

263 Metabolomic profiling has the potential to provide insights into the physiological
264 drivers associated with the alterations that affect bacterial growth in presence of NAC.
265 Indeed, our results show that the metabolome of *X. citri* cells was significantly impacted by
266 NAC compared to control, as verified in PCA and OPLS models (Fig. 3). Taken as a whole,
267 the NAC metabolomics signature is characterized by a decrease in amino acids such as
268 glutamine, L-proline, L-leucine, L-valine, L-lysine, lyxosylamine and tyrosine. The amino
269 acids L-leucine and L-valine are two of the three (L-isoleucine) essential branched-chain
270 amino acids (BCAA) required for the growth and survival of bacteria³⁵. It has been
271 demonstrated that the enzymes belonging to the BCAA biosynthetic pathway in bacteria are
272 an excellent potential source of targets to be explored for development of new antibacterial
273 agents³⁵. The action of NAC in BCAA could be due to its thiol group, since the threonine
274 dehydratase/deaminase, an enzyme that plays an essential role in the biosynthetic pathway
275 of BCAAs in microorganisms, is competitively inhibited by aminothiols^{36,37}. Therefore, the
276 potential of NAC as an aminothiol could be better explored to interfere on BCAA

277 biosynthesis of pathogenic bacteria. Similarly, we suggest that the decrease of the other
278 amino acids in presence of NAC, could be also due the interference of the excess of thiol
279 group in the enzymes involved with amino acids biosynthesis or protein synthesis. As these
280 amino acids are sole for carbon, energy, and nitrogen resources, as well as protein syntheses,
281 their decrease could explain the significant damage in cells growth observed in this study.
282 It is well known that high levels of intracellular cysteine present cytotoxicity to bacteria ³⁸.
283 The increase of cysteine derived from NAC addition explains the *X. citri* growth inhibition,
284 which could be due either to the amino acid starvation and to the oxidative DNA damage
285 because of the cysteine cytotoxicity ^{39, 40}. It is worth mentioning that addition of NAC and
286 the consequent increase of cysteine correlates with absence of glutamine and increasing of
287 glutathione. It is known that cysteine and glutamine are both necessary to glutathione
288 biosynthesis. Since NAC leads to an increase of cysteine levels and glutathione also
289 increases, we suggest that the absence of glutamine results from its use for the glutathione
290 biosynthesis, reducing its pool to a non-detectable level. This increase of cysteine due to
291 NAC addition could change the homeostasis of intracellular cysteine, inducing oxidative
292 stress and leading to cell death, similar to the observed by Park and Imlay ⁴⁰.

293 The main deregulated metabolic pathways during time course of NAC treatment were
294 arginine and proline, alanine, aspartate and glutamate, D-glutamine and D-glutamate, purine,
295 pyrimidine as well as nitrogen metabolisms (Fig. 5). Curiously, these pathways are somehow
296 linked with nitrogen metabolism. In the cells inorganic nitrogen is assimilated into glutamate
297 and glutamine, which are the major intracellular nitrogen donor ^{41, 42}. Glutamate is a precursor
298 for arginine, glutamine, proline, and the polyamines. Glutamate degradation is also important
299 for cell survival in acidic environments, and changes in glutamate concentration accompany
300 changes in osmolarity ⁴³ that could cause cells death.

301 In our study we demonstrated that NAC without the interference of acid pH affected
302 bacterial growth disturbing the metabolic activity, especially for carbon and nitrogen
303 pathways. We show that NAC was able to act as antimicrobial molecule without initially
304 affecting cell membranes but acting on targets in the cell. We suggest that, as verified for
305 BCAA, as an aminothiols drug, NAC would be interfering with other enzymes more
306 susceptible to competition with thiol altering its function and metabolism. In addition, the
307 reducing property through its thiol-disulfide exchange can interact with target proteins with

308 cysteine residue or thiol group via a thioldisulfide exchange reaction harming protein
309 functions ⁴⁴. In this case, NAC action is actually dependent on modulating the redox states
310 of cysteine residues of target proteins ⁴⁵. Possibly the antimicrobial effect of NAC in bacterial
311 cell is associate with the NAC concentration, where a dose that is high and toxic for bacteria
312 is low and beneficial for superior organism cells ^{16, 18, 46}. This work shows for the first time
313 the molecular mechanisms in which NAC works as an antimicrobial molecule. The results
314 showed in this study open new possibilities to better explore the potential of NAC to reach
315 specific targets improving its efficiency and specificity to kill pathogenic bacteria. It is
316 particularly important in a scenario where the necessity of non-antibiotic drugs is increasing
317 face the constant occurrence of resistant bacteria. In addition, NAC has a well-described
318 antioxidant and radical scavenging activity in eukaryotic cells, it is quite stable, inexpensive,
319 and safe ¹⁶, features that encourage its improvement as antimicrobial compound. Even though
320 NAC has been used for a long time in medicine, its use in agriculture was only recently
321 investigated ^{8, 17, 47, 48, 49}. Thus, the potential of NAC in agriculture could be also better
322 explored aiming to incorporate practice to control phytopathogenic bacteria or improve plant
323 heathy to produce food in a more sustainable way ^{50, 51}.

324

325 **Material and Methods**

326 **Growth curve and culture conditions.** Inoculation was carried out by the addition of a
327 single isolated colony of *Xanthomonas citri* subsp. *citri* strain 306 ⁵² into 10 mL of NBY
328 nutrient medium ⁵³ and grown overnight at 28°C. The cell suspension was centrifuged, and
329 the pellet was adjusted to an optical density (OD) of 0.1 (Abs 600nm), corresponding to a
330 bacterial concentration of approximately 10⁶ CFU/mL. Each well of a 96-well microtiter plate
331 containing NAC (8.0 mg/mL) was inoculated with 200 µL of the *X. citri* suspension. The
332 growth was monitored at 0, 1, 2, 4, 6, 12, and 24 hours of incubation at 28°C by measuring
333 the OD at 600 nm in a Varioskan Flash (Thermo Scientific). An aliquot from the same
334 samples was collected for serial dilution and plated on NBY media. The plates were
335 incubated at 28°C for 48 hours, followed by CFU counting. Controls (bacterial suspension
336 without NAC) were also included in all evaluations. Three biological experiments with two
337 technical replicates were performed.

338

339 **Live and dead.** The Live/Dead BacLight kit (Thermo- Scientific L7012) was used to evaluate
340 the bacterial membrane integrity after incubation with NAC, pH=6.8. The experiment was
341 performed as described by Nazaré et al ⁵⁴. Briefly *X. citri* with an initial inoculum of 10⁶
342 CFU/mL were submitted to 4, 6, 12, and 24 hours with 8 mg/mL of NAC, as described above.
343 Mixtures of SYTO 9 and propidium iodide (PI) were incubated with the samples as specified
344 (Thermo Fisher Scientific, USA). SYTO 9 (blue) can stain nucleic acids with intact or
345 damaged membranes, while PI is an intercalating agent that stains the nucleic acid only in
346 bacteria with damaged membranes and thus it is used to differentiate cells with permeabilized
347 membranes. The samples were immobilized in agarose-covered slides as described by
348 Martins et al ⁵⁵. The cells were visualized using an Olympus BX-61 optical microscope,
349 equipped with a monochromatic OrcaFlash- 2.8 camera (Hamamatsu, Japan). The images
350 were recorded and analyzed using the software CellSens version 11 (Olympus). At least
351 1,000 cells were counted for each sample (n>1000).

352

353 **Sample preparation.** Growth of *X. citri* for metabolomic analysis in presence of 8 mg/mL
354 of NAC, pH=6.8 were cultured in 20 mL of NBY at 28°C for 24 h. The growth condition was
355 exactly the same as describe above for growth curve. Aliquots of 1 mL were collected at 0,
356 1, 2, 4, 6, 12, and 24 hours for metabolite extraction and another aliquot was collected, plated
357 on NBY solid medium to certify the NAC effect. For metabolite extraction, 1 mL of bacterial
358 cell culture was sampled and filtered in PTFE membrane with 0.22 µm pores. Bacterial
359 pellets were extracted in 1 mL of a precooled (-15°C) mixture of methyl tert-butyl
360 ether:methanol:H₂O 3:1:1 (v/v/v), as previously described by Hummel et al ⁵⁶. An aliquot of
361 100µL of the organic phase was dried and derivatized as described in Roessner et al ²⁸.

362

363 **GC-TOF/MS analysis.** An aliquot of 1µL of each derivatized sample was injected in a
364 splitless mode by autosampler Combi-PAL Agilent (Waldbronn, Germany) into an Agilent
365 7890 gas chromatograph coupled to a Pegasus II time-of-flight (TOF) mass spectrometer
366 (Leco Corp., St. Joseph, MI, USA). Chromatogram acquisition parameters were described as
367 Weckwerth et al ⁵⁷. Prior to the analysis, biological samples were randomized. Quality
368 controls, including blanks, pool of samples and mix of standards, including NAC were
369 analyzed at the beginning of the run and after every 10 samples and were used to assess the

370 quality of the run and performance of the equipment. Chromatograms were exported using
371 the Leco ChromaTOF software (version 3.25) in .cdf files.

372

373 **For targeted analysis cdf.** Files were imported into R software. Peak detection, retention
374 time alignment, and library matching were performed using Target Search R-package ³⁰.
375 Peaks were manually validated using a reference library derived from the Golm Metabolome
376 Database ²⁹. Metabolites were quantified by the peak intensity of a selective mass.
377 Metabolites intensities were normalized by dividing the OD of each biological replicate,
378 followed by the sum of total ion count and log₂ transformed.

379

380 **For untargeted analysis.** The cdf files were then processed using MZmine 2.10 for peak
381 detection, peak filtering, chromatogram construction, chromatogram deconvolution and
382 alignment. The parameters used for data processing followed the method previously
383 described by Elie, Santerre and Touboul ³³. The resulting data set (Retention time x MS
384 signal intensities) of the 80 samples generated in a peaklist of 2235 features with associated
385 MS spectra. This resulting peaklist was exported as input for Molecular Network multivariate
386 data analysis and Molecular Network generation.

387 Pathway analysis integrating enrichment analysis was performed using global test
388 algorithms and topology analysis using relative-betweenness centrality algorithm using
389 *Pseudomonas putida* KT2440 as reference pathway database library.

390

391 **Molecular Networking and metabolite annotation.** A molecular network (MN) was
392 created with the gas chromatography workflow available at Global Natural Products Social
393 Molecular Networking (GNPS) (<https://gnps.ucsd.edu>). The spectra data was filtered by
394 removing all MS/MS fragment ions within +/- 17 Da of the precursor m/z. MS/MS spectra
395 were window filtered by choosing only the top 6 fragment ions in the +/- 50 Da window
396 throughout the spectrum. The precursor ion mass tolerance was set to 20000 Da and the
397 MS/MS fragment ion tolerance to 0.5 Da. A MN was then created where edges were filtered
398 to have a cosine score above 0.7 and more than 6 matched peaks. Further, edges between two
399 nodes were kept in the network if and only if each of the nodes appeared in each other's
400 respective top 10 most similar nodes. Finally, the maximum size of a molecular family was

401 set to 100, and the lowest scoring edges were removed from molecular families until the
402 molecular family size was below this threshold. The library spectra were filtered in the same
403 manner as the input data. All matches kept between network spectra and library spectra were
404 required to have a score above 0.75 and at least 6 matched peaks. The molecular networks
405 were visualized using Cytoscape software version 3.8.0⁵⁸.

406

407 **Acknowledgements**

408 We thank Lúcia Daniela Wolf from Laboratório Nacional de Biorrenováveis (LNBR) for
409 GC-TOF/MS analysis assistance and Caio Felipe Cavicchia Zamuner, PhD student from
410 Departamento de Bioquímica e Microbiologia, Instituto de Biociências, Universidade
411 Estadual Paulista (UNESP), for microscopy analysis assistance. This work was supported by
412 a research grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo
413 (2013/10957-0) and INCT-Citros (Fapesp 2014/50880-0 and CNPq 465440/2014-2). SCP
414 and LLS were postdoctoral fellow supported by FAPESP (2013/01395-9 and 2018/10734-
415 5). MAT and AAS are recipient of research fellowships from CNPq.

416

417 **Author contributions**

418 S.C.P., M.A.T., C.C. and A.A.S. designed the experiments. S.C.P. and M.S.S performed the
419 experiments. S.C.P., A.A.S., L.L.S. and C.C analyzed the results. S.C.P., L.L.S., H.F.
420 M.A.T., C.C., and A.A.S., discussed the data and wrote the manuscript.

421

422 **Competing interests**

423 The authors declare no competing interests.

424

425

426 **Additional information**

427 Supplementary Information in attached files

428

429

430 **References**

- 431 1. Koch, C. & Høiby, N. Pathogenesis of cystic fibrosis. *Lancet*. **341**, 1065-1069.
432 [https://doi.org/10.1016/0140-6736\(93\)92422-p](https://doi.org/10.1016/0140-6736(93)92422-p) (1993).
- 433 2. de Souza, A. A., Takita, M. A., Coletta-Filho, H. D. *et al.* Analysis of gene expression
434 in two growth states of *Xylella fastidiosa* and its relationship with pathogenicity.
435 [published correction appears in *Mol Plant Microbe Interact.* 2003

- 436 Nov;16(11):1047]. *Mol. Plant. Microbe Interact.* **16**, 867-875.
437 [https://doi:10.1094/MPMI.2003.16.10.867](https://doi.org/10.1094/MPMI.2003.16.10.867) (2003).
- 438 3. Parsek, M. R. & Singh, P. K. Bacterial biofilms: an emerging link to disease
439 pathogenesis. *Annu. Rev. Microbiol.* **57**, 677-701.
440 [https://doi:10.1146/annurev.micro.57.030502.090720](https://doi.org/10.1146/annurev.micro.57.030502.090720) (2003).
- 441 4. Newman, K. L., Almeida, R. P., Purcell, A. H. & Lindow, S. E. Cell-cell signaling
442 controls *Xylella fastidiosa* interactions with both insects and plants. *Proc. Natl. Acad.*
443 *Sci. U. S. A.* **101**, 1737-1742. [https://doi:10.1073/pnas.0308399100](https://doi.org/10.1073/pnas.0308399100) (2004).
- 444 5. Fletcher, M. The physiological activity of bacteria attached to solid surfaces. *Adv.*
445 *Microb. Physiol.* **32**, 53-85. [https://doi:10.1016/s0065-2911\(08\)60005-3](https://doi.org/10.1016/s0065-2911(08)60005-3) (1991).
- 446 6. Stewart, P. S. Mechanisms of antibiotic resistance in bacterial biofilms. *Int. J. Med.*
447 *Microbiol.* **292**, 107-113. [https://doi:10.1078/1438-4221-00196](https://doi.org/10.1078/1438-4221-00196) (2002).
- 448 7. Rodrigues, C. M., Takita, M. A., Coletta-Filho, H. D. *et al.* Copper resistance of
449 biofilm cells of the plant pathogen *Xylella fastidiosa*. *Appl. Microbiol. Biotechnol.*
450 **77**, 1145-1157. [https://doi:10.1007/s00253-007-1232-1](https://doi.org/10.1007/s00253-007-1232-1) (2008).
- 451 8. Muranaka, L. S., Giorgiano, T. E., Takita, M. A. *et al.* N-acetylcysteine in agriculture,
452 a novel use for an old molecule: focus on controlling the plant-pathogen *Xylella*
453 *fastidiosa*. *PLoS One.* **8**, e72937. [https://doi:10.1371/journal.pone.0072937](https://doi.org/10.1371/journal.pone.0072937) (2013).
- 454 9. Kundukad, B., Schussman, M., Yang, K. *et al.* Mechanistic action of weak acid drugs
455 on biofilms. *Sci. Rep.* **7**, 4783. [https://doi:10.1038/s41598-017-05178-3](https://doi.org/10.1038/s41598-017-05178-3) (2017).
- 456 10. Martins, P. M. M., de Oliveira Andrade, M., Benedetti, C. E. *et al.* *Xanthomonas*
457 *citri* subsp. *citri*: host interaction and control strategies. *Trop. plant pathol.* **45**, 213–
458 236. <https://doi.org/10.1007/s40858-020-00376-3> (2020).
- 459 11. Malamud, F., Torres, P. S., Roeschlin, R. *et al.* The *Xanthomonas axonopodis* pv.
460 *citri* flagellum is required for mature biofilm and canker development. *Microbiology.*
461 **157**, 819-829. [https://doi:10.1099/mic.0.044255-0](https://doi.org/10.1099/mic.0.044255-0) (2011).
- 462 12. Li, J. & Wang, N. Genome-wide mutagenesis of *Xanthomonas axonopodis* pv. *citri*
463 reveals novel genetic determinants and regulation mechanisms of biofilm
464 formation. *PLoS One.* **6**, e21804. [https://doi:10.1371/journal.pone.0021804](https://doi.org/10.1371/journal.pone.0021804) (2011).
- 465 13. Granato, L. M., Picchi, S. C., Andrade, M. de O. *et al.* The ATP-dependent RNA
466 helicase HrpB plays an important role in motility and biofilm formation in

- 467 *Xanthomonas citri* subsp. *citri*. *BMC Microbiol.* **16**, 55. [https://doi:10.1186/s12866-](https://doi:10.1186/s12866-016-0655-1)
468 016-0655-1 (2016).
- 469 14. Granato, L. M., Picchi, S. C., Andrade, M. de O. *et al.* The *ecnA* Antitoxin Is
470 Important Not Only for Human Pathogens: Evidence of Its Role in the Plant
471 Pathogen *Xanthomonas citri* subsp. *citri*. *J. Bacteriol.* **201**, e00796-18.
472 <https://doi:10.1128/JB.00796-18> (2019).
- 473 15. Gottwald, T. R., Graham, J. H., Bock, C., Bonn, G., Civerolo, E., Irey, M., Leite, R.,
474 McCollum, G., Parker, P., Ramallo, J., Riley, T., Schubert, T., Stein, B., & Taylor,
475 E. The epidemiological significance of postpackinghouse survival of *Xanthomonas*
476 *citri* subsp. *citri* for dissemination of Asiatic citrus canker via infected fruit. *Crop*
477 *Prot.* **28**, 508-524 (2009).
- 478 16. Aldini, G., Altomare, A., Baron, G. *et al.* N-Acetylcysteine as an antioxidant and
479 disulphide breaking agent: the reasons why. *Free Radic. Res.* **52**, 751-762.
480 <https://doi:10.1080/10715762.2018.1468564> (2018).
- 481 17. Picchi, S. C., Takita, M. A., Coleta-Filho, H. D., Machado, M. A. & de Souza, A. A.
482 N -acetylcysteine interferes with the biofilm formation, motility and epiphytic
483 behaviour of *Xanthomonas citri* subsp. *citri*. *Plant Pathology.* **65**, 561–569.
484 <https://doi.org/10.1111/ppa.12430> (2016).
- 485 18. Zafarullah, M., Li, W. Q., Sylvester, J. & Ahmad, M. Molecular mechanisms of N-
486 acetylcysteine actions. *Cell Mol. Life Sci.* **60**, 6-20.
487 <https://doi:10.1007/s000180300001> (2003).
- 488 19. Quah, S. Y., Wu, S., Lui, J. N., Sum, C. P. & Tan, K. S. N-acetylcysteine inhibits
489 growth and eradicates biofilm of *Enterococcus faecalis*. *J. Endod.* **38**, 81-85.
490 <https://doi:10.1016/j.joen.2011.10.004> (2012).
- 491 20. Eroshenko, D., Polyudova, T. & Korobov, V. N-acetylcysteine inhibits growth,
492 adhesion and biofilm formation of Gram-positive skin pathogens. *Microb. Pathog.*
493 **105**, 145-152. <https://doi:10.1016/j.micpath.2017.02.030> (2017).
- 494 21. Lea, J., Conlin, A. E., Sekirov, I. *et al.* In vitro efficacy of N-acetylcysteine on
495 bacteria associated with chronic suppurative otitis media. *J. Otolaryngol. Head Neck*
496 *Surg.* **43**, 20. <https://doi:10.1186/1916-0216-43-20> (2014).

- 497 22. Drago, L., De Vecchi, E., Mattina, R. & Romanò, C. L. Activity of N-acetyl-L-
498 cysteine against biofilm of *Staphylococcus aureus* and *Pseudomonas aeruginosa* on
499 orthopedic prosthetic materials. *Int. J. Artif. Organs.* **36**, 39-46.
500 <https://doi:10.5301/ijao.5000135> (2013).
- 501 23. Aslam, S. & Darouiche, R. O. Role of antibiofilm-antimicrobial agents in controlling
502 device-related infections. *Int. J. Artif. Organs.* **34**, 752-758.
503 <https://doi:10.5301/ijao.5000024> (2011).
- 504 24. Zhao, T. & Liu, Y. N-acetylcysteine inhibit biofilms produced by *Pseudomonas*
505 *aeruginosa*. *BMC Microbiol.* **10**, 140. <https://doi:10.1186/1471-2180-10-140> (2010).
- 506 25. Ercan, U. K., Ji, H. W. H., Fridman, G., Brooks, A. D. & Joshi, S.G. Nonequilibrium
507 Plasma-Activated Antimicrobial Solutions are Broad-Spectrum and Retain their
508 Efficacies for Extended Period of Time. *Plasma Processes and Polymers.* **10**, 544-
509 555. <https://doi.org/10.1002/ppap.201200104> (2013).
- 510 26. Ercan, U. K., Smith, J., Ji, H. F., Brooks, A. D. & Joshi, S. G. Chemical Changes in
511 Nonthermal Plasma-Treated N-Acetylcysteine (NAC) Solution and Their
512 Contribution to Bacterial Inactivation. *Sci. Rep.* **6**, 20365.
513 <https://doi:10.1038/srep20365> (2016).
- 514 27. Saldanha, L. L., Allard, P. M., Afzan, A., de Melo, F. P. S. R., Marcourt, L., Queiroz,
515 E. F., Vilegas, W., Furlan, C. M., Dokkedal, A. L. & Wolfender, J. L. Metabolomics
516 of *Myrcia bella* Populations in Brazilian Savanna Reveals Strong Influence of
517 Environmental Factors on Its Specialized Metabolism. *Molecules.* **25**, 2954.
518 <https://doi:10.3390/molecules25122954> (2020).
- 519 28. Roessner, U., Luedemann, A., Brust, D. *et al.* Metabolic profiling allows
520 comprehensive phenotyping of genetically or environmentally modified plant
521 systems. *Plant Cell.* **13**, 11-29. <https://doi:10.1105/tpc.13.1.11> (2001).
- 522 29. Kopka, J., Schauer, N., Krueger, S., Birkemeyer, C., Usadel, B., Bergmüller, E.,
523 Dörmann, P., Weckwerth, W., Gibon, Y., Stitt, M., Willmitzer, L., Fernie, A. R. &
524 Steinhauser, D. GMD@CSB.DB: the Golm Metabolome Database. *Bioinformatics.*
525 **21**, 1635-8. <https://doi:10.1093/bioinformatics/bti236> (2005).

- 526 30. Cuadros-Inostroza, A., Caldana, C., Redestig, H. *et al.* TargetSearch-a Bioconductor
527 package for the efficient preprocessing of GC-MS metabolite profiling data. *BMC*
528 *Bioinformatics*. **10**, 428. <https://doi:10.1186/1471-2105-10-428> (2009).
- 529 31. Forchhammer, K. Glutamine signalling in bacteria. *Front. Biosci.* **12**, 358-70.
530 <https://doi:10.2741/2069>. PMID: 17127304 (2007).
- 531 32. Fox Ramos, A. E., Evanno, L., Poupon, E., Champy, P. & Beniddir, M. A. Natural
532 products targeting strategies involving molecular networking: different manners, one
533 goal. *Nat. Prod. Rep.* **36(7)**, 960-980. <https://doi:10.1039/c9np00006b> (2019).
- 534 33. Elie, N., Santerre, C. & Touboul, D. Generation of a Molecular Network from
535 Electron Ionization Mass Spectrometry Data by Combining MZmine2 and MetGem
536 Software. *Anal. Chem.* **91**, 11489-11492. <https://doi:10.1021/acs.analchem.9b02802>
537 (2019).
- 538 34. Wang, M., Carver, J. J., Phelan, V. V., Sanchez, L. M., Garg, N., Peng, Y., Nguyen,
539 D. D. *et al.* "Sharing and community curation of mass spectrometry data with Global
540 Natural Products Social Molecular Networking." *Nature biotechnology*. **34**, 828-837.
541 <https://doi.org/10.1038/nbt.3597> (2016).
- 542 35. Franco Amorim, T. M. & Blanchard, J. S. Bacterial Branched-Chain Amino Acid
543 Biosynthesis: Structures, Mechanisms, and Drugability. *Biochemistry*. **56**, 5849-
544 5865. <https://doi:10.1021/acs.biochem.7b00849> (2017).
- 545 36. Leoncini, R., Pagani, R., Marinello, E. & Keleti, T. Double inhibition of L-threonine
546 dehydratase by aminothiols. *Biochim. Biophys. Acta.* **994**, 52-58.
547 [https://doi:10.1016/0167-4838\(89\)90061-7](https://doi:10.1016/0167-4838(89)90061-7) (1989).
- 548 37. Harris, C. L. Cysteine and growth inhibition of *Escherichia coli*: threonine deaminase
549 as the target enzyme. *J. Bacteriol.* **145**, 1031-1035
550 <https://doi:10.1128/JB.145.2.1031-1035.1981>. (1981).
- 551 38. Takumi, K., Ziyatdinov, M. K., Samsonov, V. & Nonaka, G. Fermentative Production
552 of Cysteine by *Pantoea ananatis*. *Appl. Environ. Microbiol.* **83**, e02502-16.
553 <https://doi:10.1128/AEM.02502-16> (2017).
- 554 39. Sørensen, M. A. & Pedersen, S. Cysteine, even in low concentrations, induces
555 transient amino acid starvation in *Escherichia coli*. *J. Bacteriol.* **173**, 5244-5246.
556 <https://doi:10.1128/jb.173.16.5244-5246.1991> (1991).

- 557 40. Park, S. & Imlay, J. A. High levels of intracellular cysteine promote oxidative DNA
558 damage by driving the fenton reaction. *J. Bacteriol.* **185**, 1942-1950. [https://doi:](https://doi:10.1128/jb.185.6.1942-1950.2003)
559 [10.1128/jb.185.6.1942-1950.2003](https://doi:10.1128/jb.185.6.1942-1950.2003) (2003).
- 560 41. Merrick, M. J. & Edwards, R. A. Nitrogen control in bacteria. *Microbiol. Rev.* **59**,
561 604-622 (1995).
- 562 42. van Heeswijk, W. C., Westerhoff, H. V. & Boogerd, F. C. Nitrogen assimilation in
563 *Escherichia coli*: putting molecular data into a systems perspective. *Microbiology*
564 *and molecular biology reviews.* **77**, 628–695. [https://doi.org/10.1128/MMBR.00025-](https://doi.org/10.1128/MMBR.00025-13)
565 [13](https://doi.org/10.1128/MMBR.00025-13) (2013).
- 566 43. Reitzer, L. Biosynthesis of Glutamate, Aspartate, Asparagine, L-Alanine, and D-
567 Alanine. *EcoSal Plus.* **1**(1). <https://doi:10.1128/ecosalplus.3.6.1.3> (2004).
- 568 44. Sun, Shi-Yong. N-acetylcysteine, reactive oxygen species and beyond. *Cancer Biol.*
569 *Ther.* **9** (2), 109-10. <https://doi:10.4161/cbt.9.2.10583> (2010).
- 570 45. Kim, K. Y., Rhim, T., Choi, I. & Kim, S. S. N-acetylcysteine induces cell cycle arrest
571 in hepatic stellate cells through its reducing activity. *J. Biol. Chem.* **276**, 40591-
572 40598. <https://doi:10.1074/jbc.M100975200> (2001).
- 573 46. Tirouvanziam, R., Conrad, C. K., Bottiglieri, T., Herzenberg, L. A., Moss, R. B. &
574 Herzenberg, L. A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates
575 inflammation in cystic fibrosis. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 4628-4633.
576 <https://doi:10.1073/pnas.0511304103> (2006).
- 577 47. Nozulaidi, M., Jahan, M. S., Khairi, M., Khandaker, M. M., Nashriyah, M. & Khanif,
578 Y. M. N-acetylcysteine increased rice yield. *Turk. J. Agric. For.* **39**, 204-211. [https://](https://doi:10.3906/tar-1402-48)
579 doi:10.3906/tar-1402-48 (2015).
- 580 48. Colak, N., Torun, H., Gruz, J., Strnad, M. & Ayaz, F. A. Exogenous N-Acetylcysteine
581 alleviates heavy metal stress by promoting phenolic acids to support antioxidant
582 defence systems in wheat roots. *Ecotoxicol. Environ. Saf.* **181**, 49-59.
583 <https://doi:10.1016/j.ecoenv.2019.05.052> (2019).
- 584 49. Qiao, K., Liu, Q., Xia, Y. & Zhang, S. Evaluation of a Small-Molecule Compound,
585 N-Acetylcysteine, for the Management of Bacterial Spot of Tomato Caused by
586 Copper-Resistant *Xanthomonas perforans*. *Plant Dis.* **105**(1), 108-113. [https://doi:](https://doi:10.1094/PDIS-05-20-0928-RE)
587 [10.1094/PDIS-05-20-0928-RE](https://doi:10.1094/PDIS-05-20-0928-RE) (2021).


- 588 50. The FAO Action Plan on Antimicrobial Resistance 2016-2020.
589 <http://www.fao.org/3/a-i5996e.pdf>
- 590 51. O'Neill, J. Antimicrobials in agriculture and the environment: reducing unnecessary
591 use and waste / the Review on Antimicrobial Resistance chaired by Jim O'Neill.
592 *Review on Antimicrobial Resistance*. <https://wellcomecollection.org/works/x88ast2u>
593 (2015)
- 594 52. da Silva, A. C., Ferro, J. A, Reinach, F. C. *et al.* Comparison of the genomes of two
595 *Xanthomonas* pathogens with differing host specificities. *Nature*. **417**, 459-463.
596 <https://doi:10.1038/417459a> (2002).
- 597 53. Vidaver, A. K. Synthetic and complex media for the rapid detection of fluorescence
598 of phytopathogenic pseudomonads: effect of the carbon source. *Appl. Microbiol.* **15**,
599 1523-1524 (1967).
- 600 54. Nazaré, A. C., Polaquini, C. R., Cavalca, L. B. *et al.* Design of Antibacterial Agents:
601 Alkyl Dihydroxybenzoates against *Xanthomonascitri* subsp. *citri*. *Int. J. Mol. Sci.* **19**,
602 3050. <https://doi:10.3390/ijms19103050> (2018).
- 603 55. Martins, P. M., Lau, I. F., Bacci, M. *et al.* Subcellular localization of proteins labeled
604 with GFP in *Xanthomonas citri* ssp. *citri*: targeting the division septum. *FEMS*
605 *Microbiol. Lett.* **310**, 76-83. <https://doi:10.1111/j.1574-6968.2010.02047.x> (2010).
- 606 56. Hummel, J., Segu, S., Li, Y., Irgang, S., Jueppner, J. & Giavalisco, P. Ultra
607 performance liquid chromatography and high resolution mass spectrometry for the
608 analysis of plant lipids. *Front. Plant Sci.* **2**, 54. <https://doi:10.3389/fpls.2011.00054>
609 (2011).
- 610 57. Weckwerth, W., Wenzel, K. & Fiehn, O. Process for the integrated extraction,
611 identification and quantification of metabolites, proteins and RNA to reveal their co-
612 regulation in biochemical networks. *Proteomics*. **4**, 78-83. [https://doi:](https://doi:10.1002/pmic.200200500)
613 [10.1002/pmic.200200500](https://doi:10.1002/pmic.200200500) (2004).
- 614 58. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin,
615 N., Schwikowski, B. & Ideker, T. Cytoscape: a software environment for integrated
616 models of biomolecular interaction networks. *Genome Res.* **13**, 2498-504. [https://doi:](https://doi:10.1101/gr.1239303)
617 [10.1101/gr.1239303](https://doi:10.1101/gr.1239303) (2003).
- 618

619

620 **Figure legends**

621

622



623

624

625 **Figure 1.** Growth curve profiles of *Xanthomonas citri* subsp. *citri* in presence of NAC. Six
626 time points 1, 2, 4, 6 12 and 24 hours were evaluated after 8 mg/mL of NAC addition as well
627 as non-treated control through OD and CFU measures. After 6 h, a significant lower growth
628 was observed for the bacteria treated with NAC ($P < 0.001$).

629

630

631

632

633

634



635

636

637

638

639




640

641


642 **Figure 2.** Cellular permeability of *Xanthomonas citri* subsp. *citri* in the presence of 8 mg/mL
 643 of N-Acetylcysteine (NAC). (a) Live/Dead staining was performed on *X. citri* cells following
 644 a 0 - 24 h incubation with NAC. Blue-stained cells have intact membranes, whereas red-
 645 stained cells exhibit permeabilized membranes. Magnification of 100X; the scale bars on
 646 each panel represent 5 μ m. (b) Percentage of living or dead bacterial cells following 4 - 24 h
 647 exposure to 8 mg/mL of NAC. At least 1,000 bacterial cells were counted under a
 648 fluorescence microscope ($n > 1000$). The mean of two experiments with five technical
 649 replicates is shown. Asterisks show statistically significant differences using *t*-Student (***)
 650 $P < 0.001$). Error bars represent the standard errors of the means.

651
652
653



654
655
656
657
658
659
660
661
662
663
664
665
666
667

Figure 3. Hierarchical Clustering Analysis (a) and Principal Component Analysis (b) HCA was performed by average linkage clustering method using Euclidean distance. Samples are named according to the time points (hours) and colored coded according to treatment (before treatment -gray; control-blue and NAC-red).



668

669

670 **Figure 4.** K-means clustering to infer pattern of metabolites during *X. citri* growth. Graphs
 671 represent the metabolite pattern normalized to its respective time point 0 (i.e., before
 672 treatment), which are displayed in gray. The mean of each cluster is represented by the black
 673 lines. The identity of metabolites grouped in each cluster are presented in Supplementary
 674 Table S3.

675

676

677

678

679

680

681


682

683

684

685

686



687

688

689

690

691 **Figure 5.** Heat map of metabolic responses to the control or NAC treated cells along 24h *X.*


692 *citri* growth. Metabolite levels were normalized by the mean of all samples from given

693 metabolite and log₂ transformed. Values are means of up to 5 biological replicates. Red and

694 blue colors represent increase and decrease of metabolites, respectively. Samples are

695 arranged according to the treatment. Metabolites are grouped according to the HCA

696 clustering.



698

699


700 **Figure 6.** Selected clusters (MN₁-MN₁₀) from the statistically informed molecular network.
 701 VIP values greater than 1 (as seen in VIP plot) from the OPLS analysis were integrated in
 702 the molecular network and were differentiated through the node size. Larger nodes indicate
 703 features with VIP values greater than 1. Annotation of compounds was performed by
 704 comparison against Global Natural Products Social Molecular Networking spectral libraries.
 705 Green or rose indicate the relative mass signal intensity in NAC treatment and untreated
 706 control group, respectively. The bar chart next to the node in blue represents the mean relative
 707 intensity of the mass signal at times 0, 1, 2, 4, 6, 12, and 24 hours of the NAC treatment
 708 group. The name of the identified metabolites with cosine > 0.75 is given in the boxes.

709

710

711

712



713

714

715

716 **Figure 7.** Pathway analysis of altered metabolites of *Xanthomonas citri* subsp. *citri* incubated

717 with N-Acetylcysteine (NAC). The graph summarizes the pathways analyzed with

718 MetaboAnalyst 4.0. **(a)** Up-regulated metabolites. **(b)** Down-regulated metabolites. Larger

719 circles, higher and closer to Y-axes, show a higher impact of the concerned pathway of *X.*

720 *citri*. Colors indicate different levels of significance. The pathways with $P < 0.05$ are

721 presented.

722

Figures




Figure 1

"Please see the Manuscript PDF file for the complete figure caption".




Figure 3

"Please see the Manuscript PDF file for the complete figure caption".




Figure 4

"Please see the Manuscript PDF file for the complete figure caption".




Figure 5

"Please see the Manuscript PDF file for the complete figure caption".




Figure 6

"Please see the Manuscript PDF file for the complete figure caption".




Figure 7

"Please see the Manuscript PDF file for the complete figure caption".

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTable1.xlsx](#)
- [SupplementaryTable2.xlsx](#)
- [SupplementaryTable3.xlsx](#)
- [Supplementarytable4.pdf](#)
- [SupplementaryfiguresS1S2S3.pdf](#)